{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T22:23:57Z","timestamp":1787955837342,"version":"build-2784847793"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.jpba.2020.113337","type":"journal-article","created":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T02:43:53Z","timestamp":1588733033000},"page":"113337","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Lack of concordance between EMIT assay and LC-MS\/MS for Therapeutic Drug Monitoring of Mycophenolic Acid: Potential increased risk for graft rejection?"],"prefix":"10.1016","volume":"187","author":[{"given":"Amedeo","family":"De Nicol\u00f2","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Ianniello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Benagli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Della Bruna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Antonucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"D\u2019Avolio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Cant\u00f9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.jpba.2020.113337_bib0005","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1002\/lt.21607","article-title":"Comparison of a new enzymatic assay with a high-performance liquid chromatography\/ ultraviolet detection method for therapeutic drug monitoring of mycophenolic acid in adult liver transplant recipients","volume":"14","author":"Blanchet","year":"2008","journal-title":"Liver Transpl."},{"issue":"3","key":"10.1016\/j.jpba.2020.113337_bib0010","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1097\/01.ASN.0000051598.12824.DA","article-title":"Pharmacokinetics of mycophenolate mofetil in patients with autoimmune diseases compared renal transplant recipients","volume":"14","author":"Neumann","year":"2003","journal-title":"J. Am. Soc. Nephrol."},{"issue":"9","key":"10.1016\/j.jpba.2020.113337_bib0015","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1002\/lt.20792","article-title":"Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant patients presenting gastrointestinal disorders: a pilot study","volume":"12","author":"Dumortier","year":"2006","journal-title":"Liver Transplant."},{"issue":"11","key":"10.1016\/j.jpba.2020.113337_bib0020","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/j.1600-6143.2007.01983.x","article-title":"Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation","volume":"7","author":"Le Meur","year":"2007","journal-title":"Am. J. Transplant."},{"issue":"1","key":"10.1016\/j.jpba.2020.113337_bib0025","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/00003088-200746010-00002","article-title":"Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients","volume":"46","author":"Staatz","year":"2007","journal-title":"Clin. Pharmacokinet."},{"issue":"7","key":"10.1016\/j.jpba.2020.113337_bib0030","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/lt.20453","article-title":"Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C","volume":"11","author":"Wiesner","year":"2005","journal-title":"Liver Transpl."},{"issue":"6","key":"10.1016\/j.jpba.2020.113337_bib0035","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S0009-9236(98)90058-3","article-title":"The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation","volume":"64","author":"Hale","year":"1998","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.jpba.2020.113337_bib0040","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1600-6143.2005.01151.x","article-title":"Mycophenolic acid 12-h trough level monitoring in renal transplantation: association with acute rejection and toxicity","volume":"6","author":"Borrows","year":"2006","journal-title":"Am. J. Transplant."},{"issue":"1","key":"10.1016\/j.jpba.2020.113337_bib0045","doi-asserted-by":"crossref","first-page":"184","DOI":"10.2215\/CJN.02860806","article-title":"Therapeutic monitoring of mycophenolate mofetil","volume":"2","author":"Jeong","year":"2007","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"6","key":"10.1016\/j.jpba.2020.113337_bib0050","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2165\/00003088-199834060-00002","article-title":"Clinical pharmacokinetics of mycophenolate mofetil","volume":"34","author":"Bullingham","year":"1998","journal-title":"Clin. Pharmacokinet."},{"issue":"2","key":"10.1016\/j.jpba.2020.113337_bib0055","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2215\/CJN.07111009","article-title":"Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation","volume":"5","author":"Kuypers","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"3","key":"10.1016\/j.jpba.2020.113337_bib0060","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/clinchem\/46.3.365","article-title":"Determination of the acyl glucuronide metabolite of mycophenolic acid in human plasma by HPLC and emit","volume":"46","author":"Shipkova","year":"2000","journal-title":"Clin. Chem."},{"issue":"6","key":"10.1016\/j.jpba.2020.113337_bib0065","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/00007691-199512000-00025","article-title":"Mycophenolate mofetil: a report of the consensus panel","volume":"17","author":"Shaw","year":"1995","journal-title":"Ther. Drug Monit."},{"issue":"4","key":"10.1016\/j.jpba.2020.113337_bib0070","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/S0041-1345(98)00201-2","article-title":"Therapeutic drug monitoring of mycophenolic acid: comparison of HPLC and immunoassay reveals new MPA metabolites","volume":"30","author":"Schutz","year":"1998","journal-title":"Transplant. Proc."},{"issue":"Suppl. 1","key":"10.1016\/j.jpba.2020.113337_bib0075","doi-asserted-by":"crossref","first-page":"61S","DOI":"10.1111\/j.1365-2125.2001.00365.x","article-title":"Immunosuppressant drugs\u2013the role of therapeutic drug monitoring","volume":"52","author":"Johnston","year":"2001","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.jpba.2020.113337_bib0080","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/clinchem\/48.3.517","article-title":"Comparison of the Emit immunoassay with HPLC for therapeutic drug monitoring of mycophenolic acid in pediatric renal-transplant recipients on mycophenolate mofetil therapy","volume":"48","author":"Weber","year":"2002","journal-title":"Clin. Chem."},{"issue":"2","key":"10.1016\/j.jpba.2020.113337_bib0085","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.trre.2011.01.002","article-title":"Therapeutic drug monitoring of mycophenolates in kidney transplantation: report of the Transplantation Society consensus meeting","volume":"25","author":"Le Meur","year":"2011","journal-title":"Transplant. Rev. (Orlando)"},{"issue":"1","key":"10.1016\/j.jpba.2020.113337_bib0090","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/lt.20926","article-title":"Switch to 1.5 grams MMF monotherapy for CNI-related toxicity in liver transplantation is safe and improves renal function, dyslipidemia, and hypertension","volume":"13","author":"Orlando","year":"2007","journal-title":"Liver Transplant."},{"issue":"5","key":"10.1016\/j.jpba.2020.113337_bib0095","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0009-9120(98)00040-X","article-title":"Therapeutic monitoring of mycophenolic acid. A consensus panel report","volume":"31","author":"Shaw","year":"1998","journal-title":"Clin. Biochem."},{"issue":"2","key":"10.1016\/j.jpba.2020.113337_bib0100","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/01.ftd.0000199358.80013.bd","article-title":"Therapeutic drug monitoring of mycophenolate mofetil in transplantation","volume":"28","author":"van Gelder","year":"2006","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jpba.2020.113337_bib0105","first-page":"113","article-title":"A high-throughput U-HPLC-MS\/MS assay for the quantification of mycophenolic acid and its major metabolites mycophenolic acid glucuronide and mycophenolic acid acyl-glucuronide in human plasma and urine","volume":"883\u2013884","author":"Klepacki","year":"2011","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073170852030426X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073170852030426X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:02:39Z","timestamp":1760000559000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073170852030426X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":21,"alternative-id":["S073170852030426X"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2020.113337","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lack of concordance between EMIT assay and LC-MS\/MS for Therapeutic Drug Monitoring of Mycophenolic Acid: Potential increased risk for graft rejection?","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2020.113337","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113337"}}